ClinicalTrials.gov
ClinicalTrials.gov Menu

CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02670083
Recruitment Status : Active, not recruiting
First Posted : February 1, 2016
Last Update Posted : May 16, 2018
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

January 28, 2016
February 1, 2016
May 16, 2018
March 22, 2016
August 31, 2020   (Final data collection date for primary outcome measure)
Change from baseline to Week 105 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score [ Time Frame: Baseline, Week 105 ]
Same as current
Complete list of historical versions of study NCT02670083 on ClinicalTrials.gov Archive Site
  • Change from Baseline to Week 105 on Cognition, as assessed by Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) (subscales) 13 (ADAS-Cog-13) and 11 (ADAS-Cog-11) [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 on Severity of Dementia, Assessed Using the CDR-Gloal Score (CDR-GS) [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 on Severity of Dementia, Assessed Using the Mini Mental State Evaluation (MMSE) [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 on function as assessed by the ADCS-ADL total score and the ADCS-instrumental subscore [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 on a measure of dependence derived from the ADCS-ADL score [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q) [ Time Frame: Baseline, Week 105 ]
  • Quality of Life-Alzheimer's Disease (QoL-AD) Scale Score [ Time Frame: Baseline up to Week 105 ]
  • Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) Scale Score [ Time Frame: Baseline up to Week 105 ]
  • EQ-5D Questionnaire Domain Score [ Time Frame: Baseline up to Week 105 ]
  • Percentage of Participants with Adverse Event (AEs) and Serious Adverse Event (SAEs) [ Time Frame: Up to Week 105 ]
  • Percentage of Participants with Anti-Crenezumab Antibodies [ Time Frame: Baseline up to Week 105 ]
  • Serum Concentration of Crenezumab [ Time Frame: Pre-infusion (0 hour), 60-90 minutes post-infusion on Day 1 Week 1 and on Week 25; Weeks 5, 13, 37, 53, and 100 (infusion length = as per the Pharmacy Manual) ]
  • Plasma Amyloid Beta (Abeta) Concentrations [ Time Frame: Screening (Weeks -8 to -1) ; Day 1 Week 1; Weeks 5, 25, 53, and 100 ]
  • Change from Baseline to Week 105 in Brain Volume as Determined by Magnetic Resonance Imaging (MRI) [ Time Frame: Baseline, Week 105 ]
  • Cerebrospinal Fluid (CSF) Concentration of Crenezumab [ Time Frame: At pre-defined intervals from baseline through week 105 ]
  • Brain Amyloid Load Over Time Measured by Amyloid-PET [ Time Frame: At pre-defined intervals from baseline through week 105 ]
  • Brain Tau Load Over Time Measured by Tau-PET [ Time Frame: At pre-defined intervals from baseline through week 105 ]
  • Cerebrospinal Fluid (CSF) Markers of Disease Over Time [ Time Frame: At pre-defined intervals from baseline through week 105 ]
  • Mean change from baseline to Week 105 in Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) (subscale) 13 (ADAS-Cog-13) Score [ Time Frame: Baseline, Week 105 ]
  • Time to clinically evident decline (slowing functional and cognitive decline and disease progression), as determined by confirmed clinical decline on the MMSE scale and time to loss of activity of daily living (ADL) [ Time Frame: up to 105 weeks ]
  • Change from Baseline to Week 105 in CDR-GS [ Time Frame: Baseline, Week 105 ]
  • Mean change from baseline to Week 105 in ADAS-Cog (subscale) 12 (ADAS-Cog-12) score [ Time Frame: Baseline, Week 105 ]
  • Time to an increase of >=4 points from baseline at any time before or on Week 105 in the ADAS-Cog-13 [ Time Frame: up to Week 105 ]
  • Mean change from baseline to Week 105 in ADCS-ADL instrumental subscale score [ Time Frame: Baseline, Week 105 ]
  • Mean change from baseline to Week 105 in ADCS-ADL total score [ Time Frame: Baseline, Week 105 ]
  • Mean change from baseline to Week 105 in dependence level assessed from the ADCS-ADL score [ Time Frame: Baseline, Week 105 ]
  • Change from baseline to Week 105 in Neuropsychiatric Inventory (NPI) scores [ Time Frame: Baseline, Week 105 ]
  • Change from baseline to Week 105 in the Quality of Life-Alzheimer's Disease (QoL-AD) scale score [ Time Frame: Baseline, Week 105 ]
  • Change from baseline to Week 105 in the Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) scale score [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 in EQ-5D questionnaire domain scores [ Time Frame: Baseline, Week 105 ]
  • Percentage of participants with adverse event and serious adverse event [ Time Frame: Up to Week 105 ]
  • Mean change from baseline to Week 105 in MMSE Score [ Time Frame: Baseline, Week 105 ]
Not Provided
Not Provided
 
CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The final efficacy and safety assessment will be performed 52 weeks after the last crenezumab dose.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Alzheimer's Disease
  • Drug: Crenezumab
    Crenezumab will be administered by IV infusion q4w for 100 weeks.
  • Drug: Placebo
    Placebo will be administered as IV infusion q4w for 100 weeks.
  • Experimental: Crenezumab
    Participants will receive IV infusion of crenezumab q4w for 100 weeks.
    Intervention: Drug: Crenezumab
  • Placebo Comparator: Placebo
    Participants will receive placebo q4w for 100 weeks.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
813
750
July 31, 2021
August 31, 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Weight between 40 and 120 kilograms (Kg) inclusive
  • Availability of a person (referred to as the "caregiver") who in the investigator's judgment:
  • Has frequent and sufficient contact with the participant to be able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits (which require partner input for scale completion), signs the necessary consent form, and has sufficient cognitive capacity to accurately report upon the participant's behavior and cognitive and functional abilities
  • Fluency in the language of the tests used at the study site
  • Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted)
  • Evidence of the AD pathological process, by a positive amyloid assessment either on cerebrospinal fluid (CSF) amyloid beta 1-42 levels as measured on the Elecsys beta-amyloid(1-42) test system or amyloid PET scan by qualitative read by the core/central PET laboratory
  • Demonstrated abnormal memory function at screening
  • Screening mini mental state examination (MMSE) score of greater than or equal to (>=) 22 points and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 or 1.0
  • Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment (MCI)
  • If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening

Exclusion Criteria:

  • Any evidence of a condition other than AD that may affect cognition such as other dementias, stroke, brain damage, autoimmune disorders (e.g. multiple sclerosis) or infections with neurological sequelae.
  • History of major psychiatric illness such as schizophrenia or major depression (if not considered in remission)
  • At risk of suicide in the opinion of the investigator
  • Presence of significant cerebral vascular pathology as assessed by MRI central reader
  • Unstable or clinically significant cardiovascular, kidney or liver disease (e.g., myocardial infarction)
  • Uncontrolled hypertension
  • Screening hemoglobin A1c (HbA1C) >8%
  • Poor peripheral venous access
  • History of cancer except:

If considered to be cured or If not being actively treated with anti-cancer therapy or radiotherapy

- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins

Sexes Eligible for Study: All
50 Years to 85 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Austria,   Belgium,   Bulgaria,   Canada,   Costa Rica,   Croatia,   Czechia,   Denmark,   Finland,   France,   Germany,   Hong Kong,   Hungary,   Italy,   Japan,   Korea, Republic of,   Lithuania,   Mexico,   Poland,   Portugal,   Russian Federation,   Slovenia,   Spain,   Sweden,   Switzerland,   Turkey,   Ukraine,   United Kingdom,   United States
Czech Republic
 
NCT02670083
BN29552
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
May 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP